Hdl Handle:
http://hdl.handle.net/10675.2/28
Title:
Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.
Authors:
Matsuo, Yasuhiro; Kamitani, Tetsu
Abstract:
BACKGROUND: Melanoma is the major cause of skin cancer death worldwide. Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of melanoma and Parkinson's disease, suggesting that these two diseases could share common genetic components. METHODOLOGY/PRINCIPAL FINDINGS: Recently, we found that human melanoma cell lines highly express alpha-synuclein, whereas the protein is undetectable in the non-melanoma cancer cell lines tested. To investigate the expression of alpha-synuclein in human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and normal skin. alpha-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well as in 89% of nevus sections. However, alpha-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin. CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi. Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
Citation:
PLoS One. 2010 May 5; 5(5):e10481
Issue Date:
13-May-2010
URI:
http://hdl.handle.net/10675.2/28
DOI:
10.1371/journal.pone.0010481
PubMed ID:
20463956
PubMed Central ID:
PMC2864738
Type:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
ISSN:
1932-6203
Appears in Collections:
Center for Molecular Chaperone/Radiobiology & Cancer Virology: Faculty Research and Presentations

Full metadata record

DC FieldValue Language
dc.contributor.authorMatsuo, Yasuhiroen_US
dc.contributor.authorKamitani, Tetsuen_US
dc.date.accessioned2010-09-24T21:05:58Z-
dc.date.available2010-09-24T21:05:58Z-
dc.date.issued2010-05-13en_US
dc.identifier.citationPLoS One. 2010 May 5; 5(5):e10481en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid20463956en_US
dc.identifier.doi10.1371/journal.pone.0010481en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/28-
dc.description.abstractBACKGROUND: Melanoma is the major cause of skin cancer death worldwide. Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of melanoma and Parkinson's disease, suggesting that these two diseases could share common genetic components. METHODOLOGY/PRINCIPAL FINDINGS: Recently, we found that human melanoma cell lines highly express alpha-synuclein, whereas the protein is undetectable in the non-melanoma cancer cell lines tested. To investigate the expression of alpha-synuclein in human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and normal skin. alpha-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well as in 89% of nevus sections. However, alpha-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin. CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi. Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.en_US
dc.rightsThe PMC Open Access Subset is a relatively small part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Please refer to the license statement in each article for specific terms of use. The license terms are not identical for all articles in this subset.en_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntigens, Neoplasm / metabolismen_US
dc.subject.meshBrain Neoplasms / metabolism / pathologyen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMelanins / metabolismen_US
dc.subject.meshMelanoma / metabolism / pathologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Proteins / metabolismen_US
dc.subject.meshNevus / metabolism / pathologyen_US
dc.subject.meshParkinson Disease / metabolism / pathologyen_US
dc.subject.meshPigmentationen_US
dc.subject.meshRetinoblastoma / metabolism / pathologyen_US
dc.subject.meshSkin Neoplasms / metabolism / pathologyen_US
dc.subject.meshTumor Markers, Biological / metabolismen_US
dc.subject.meshalpha-Synuclein / metabolismen_US
dc.titleParkinson's disease-related protein, alpha-synuclein, in malignant melanoma.en_US
dc.typeJournal Articleen_US
dc.typeResearch Support, N.I.H., Extramuralen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
dc.identifier.pmcidPMC2864738en_US
dc.contributor.corporatenameCenter for Molecular Chaperone/Radiobiology & Cancer Virologyen_US

Related articles on PubMed

All Items in Scholarly Commons are protected by copyright, with all rights reserved, unless otherwise indicated.